TARS

Tarsus Pharmaceuticals Inc

TARS.US tarsusrx.com + Research + Basket
CIK 0001819790
Employees 370
Phone 949 418 1801
Fiscal year end December
IPO Oct 16, 2020
Address 17700 Laguna Canyon Road, Irvine, CA, United States, 92618
74.20
+2.15 (+2.98%)
USD · NASDAQ
52-week range
53.89
91.53
Trading at 54% of the 52-week range
Market Cap
3.37B
P/E Ratio
0.00
Forward P/E
71.94
Book Value
8.01
Div. Yield
N/A
% Institutions
99.25%
% Insiders
2.69%

1 Year

+9.9%

3 Year

+425.5%

10 Year

+260.5%
Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Actions

Add an action for TARS.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman NA
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 1968
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 1978
Mr. David Nakasone Head of Investor Relations NA
Ms. Adrienne Kemp Vice President of Corporate Communications NA
Mr. Matthew Rossen M.B.A. Vice President of Marketing 1978
Mr. Scott Youmans Vice President of Sales NA
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 1977
Dr. Elizabeth Yeu-Lin M.D. Chief Medical Officer 1978
Ms. Cara Miller Senior Vice President of Corporate Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 19, 2026 Bryan Wahl N/A Sale 4.23K $67.00 $283.48K SEC
Mar 19, 2026 Dianne C Whitfield N/A Sale 4.17K $67.00 $279.66K SEC
Mar 19, 2026 Elizabeth Yeu Lin N/A Sale 390.00 $67.00 $26.13K SEC
Mar 19, 2026 Jeffrey S Farrow N/A Sale 2.19K $67.00 $146.46K SEC
Mar 19, 2026 Bobak R Azamian N/A Sale 11.96K $67.00 $801.59K SEC
Mar 18, 2026 Bobak R Azamian N/A Sale 11.67K $68.71 $801.64K SEC
Mar 18, 2026 Bryan Wahl N/A Sale 4.13K $68.71 $283.43K SEC
Mar 18, 2026 Dianne C Whitfield N/A Sale 4.07K $68.71 $279.72K SEC
Mar 18, 2026 Elizabeth Yeu Lin N/A Sale 379.00 $68.71 $26.04K SEC
Mar 18, 2026 Jeffrey S Farrow N/A Sale 2.13K $68.71 $146.56K SEC
Mar 17, 2026 Bobak R Azamian N/A Sale 10.97K $69.42 $761.68K SEC
Mar 17, 2026 Jeffrey S Farrow N/A Sale 2.11K $69.42 $146.55K SEC
Mar 17, 2026 Elizabeth Yeu Lin N/A Sale 375.00 $69.42 $26.03K SEC
Mar 17, 2026 Dianne C Whitfield N/A Sale 4.03K $69.42 $279.69K SEC
Mar 17, 2026 Bryan Wahl N/A Sale 4.08K $69.42 $283.51K SEC
Mar 16, 2026 William J Phd Link N/A Sale 12.50K $68.79 $859.88K SEC
Dec 24, 2025 Bobak R Azamian N/A Sale 6.00K $82.51 $495.06K SEC
Dec 16, 2025 Dianne C Whitfield N/A Sale 7.40K $80.10 $592.50K SEC
Sep 24, 2025 Bobak R Azamian N/A Sale 6.00K $55.37 $332.22K SEC
Sep 08, 2025 William J Phd Link N/A Sale 27.12K $57.00 $1.55M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 3.86M Jun 30, 2026 8.24% $0.00 8.54%
Deep Track Capital, LP 3.67M Jun 30, 2026 7.84% $3.36 1.85%
RTW INVESTMENTS, LLC 3.36M Jun 30, 2026 7.17% $1.80 0.33%
Jupiter Topco LLC 2.81M Jun 30, 2026 6.00% $0.07 0.00%
Paradigm Biocapital Advisors LP 2.78M Jun 30, 2026 5.93% $3.27 8.33%
HHG PLC 2.24M Mar 31, 2026 4.79% $0.08 16.09%
Assenagon Asset Management SA 1.89M Jun 30, 2026 4.05% $0.07 48.02%
Morgan Stanley - Brokerage Accounts 1.83M Jun 30, 2026 3.90% $0.01 -6.03%
Vanguard Capital Management, LLC 1.79M Jun 30, 2026 3.83% $0.00 1.85%
Jennison Associates LLC 1.66M Jun 30, 2026 3.56% $0.06 -2.83%
TANG CAPITAL MANAGEMENT LLC 1.57M Jun 30, 2026 3.35% $4.48 31.94%
Millennium Management LLC 1.43M Jun 30, 2026 3.05% $0.03 152.78%
Bank of America Corp 1.19M Jun 30, 2026 2.55% $0.00 -0.10%
Geode Capital Management, LLC 1.11M Jun 30, 2026 2.36% $0.00 -1.37%
State Street Corp 1.07M Jun 30, 2026 2.29% $0.00 9.68%
Vestal Point Capital LP 1.05M Jun 30, 2026 2.24% $1.54 425.00%
Amvescap Plc. 785.81K Jun 30, 2026 1.68% $0.00 5.83%
The Goldman Sachs Group Inc 742.69K Jun 30, 2026 1.59% $0.00 68.94%
Frazier Life Sciences Management, L.P. 728.64K Jun 30, 2026 1.56% $1.00 0.00%
D. E. Shaw & Co LP 710.56K Jun 30, 2026 1.52% $0.02 -10.19%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.40M 2.99% ▲ 7.60% Sep 30, 2026
2 iShares Russell 2000 ETF 1.08M 2.32% ▼ 1.14% Sep 30, 2026
3 Fidelity Small Cap Index 457.87K 0.98% ▲ 0.93% Jul 31, 2026
4 Janus Henderson Global Life Sciences D 409.44K 0.88% ▲ 13.88% Aug 31, 2026
5 iShares Russell 2000 Growth ETF 391.51K 0.84% ▼ 0.13% Sep 30, 2026
6 Janus Henderson Glb Life Scn I2 USD 391.09K 0.84% ▲ 13.13% Aug 31, 2026
7 PGIM Jennison Small Company A 371.98K 0.80% ▼ 8.88% Sep 30, 2026
8 Fidelity Select Health Care 360.00K 0.77% ▲ 0.00% Aug 31, 2026
9 Janus Global Life Science AUSD 346.76K 0.74% ▲ 25.92% Jun 30, 2026
10 Janus Henderson Hrzn Biotec E2 USD 322.71K 0.69% ▲ 9.77% Jun 30, 2026

Financial Highlights

▼
Market Cap: $3.37B
EBITDA: $-46.20M
Book Value: $8.01
Earnings/Share: $-1.08
Profit Margin: -7.67%
Operating Margin: -11.45%
ROA (TTM): -5.49%
ROE (TTM): -13.68%
Revenue (TTM): $606.33M
Revenue/Share (TTM): $14.12
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 69.40%

Valuation Metrics

Enterprise Value: $2.93B
Trailing P/E: 0.00
Forward P/E: 71.94

Shares Statistics

Shares Outstanding: 46.79M
Shares Float: 32.74M
% Insiders: 2.69%
% Institutions: 99.25%
Shares Short: 5.73M
Shares Short (Prior Month): 6.07M
Short Ratio: 6.62
Short % Float: 12.63%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$451.36M
Cost of Goods Sold
adjust
$-30.68M
Gross Profit
subtotal
$420.68M
SG&A
adjust
$-427.32M
R&D
adjust
$-64.32M
Operating Income
subtotal
$-70.97M
Other / Non-Operating Items
adjust
$4.55M
Net Income
subtotal
$-66.42M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TARS.US!